Video Highlights
1:11 Gary Spinner, DMSc, PA, MPH, AAHIVS
3:46 Randy Matthews, PhD, MD
4:52 Carl Schmid
|Videos|November 24, 2021
The Long-Term Prognosis of PrEP
Author(s)John Parkinson
HIV Stakeholders weigh on the future of PrEP.
Advertisement
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: Will PrEP have a prominent role and significant impact in HIV prevention?
We interviewed Gary Spinner, DMSc, PA, MPH, AAHIVS, medical director of the HIV/AIDS Program, Southwest Community Health Center, Randy Matthews, PhD, MD, senior principal scientist, Merck, and Carl Schmid, executive director, HIV+Hepatitis Policy Institute.
Check out our video to hear their insights.
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement